Neptune shifts operations
This article was originally published in The Tan Sheet
Neptune Technologies & Bioresources transfers the license for its cardiovascular application portfolio to operating subsidiary Acasti Pharma to develop active pharmaceutical ingredients for products in the Rx, OTC and medical food markets, the firm announces Aug. 21. Under the arrangement, Quebec-based Acasti will research, develop and market the APIs, with the goal of entering strategic pharmaceutical partnerships. Neptune announced a deal with Yoplait in June 2007 to provide its Neptune Krill Oil - a composition with proprietary omega-3 phospholipids - for use in functional yogurt products (1"The Tan Sheet" July 2, 2007, In Brief)
You may also be interested in...
The Canadian maker of omega-3 phospholipid ingredients announces Bayer Healthcare will commercialize its proprietary products in the U.S. Neptune Technologies & Bioresources credits its "complete portfolio of scientific data, intellectual property and regulatory approvals" with paving the way for the partnership. The firm said June 4 it expects Bayer will help broaden consumer awareness of its products, including Neptune Krill Oil and Advantage NKO dietary supplement. Neptune's strategy is "to penetrate world nutraceutical and pharmaceutical markets" through collaborations with global partners, said Henri Harland, president and CEO for the Laval, Quebec-based company. Neptune previously teamed with Yoplait on functional yogurts and shifted the license for its cardiovascular application portfolio to subsidiary Acasti Pharma (1"The Tan Sheet" Sept. 1, 2008, In Brief)
Neptune Technologies & Bioressources announces June 19 a partnership with Yoplait to develop new functional dairy products for worldwide commercialization. Yoplait will launch dairy products containing Neptune Krill Oil in "strategically chosen countries followed by a worldwide rollout," Neptune says. The firm will supply Yoplait with NKO and will receive an upfront fee as well as milestone payments and distribution royalties, Neptune states. This is not Yoplait's first venture into functional yogurt; in January Yoplait announced it added Martek's life'sDHA to its kids line (1"The Tan Sheet" Jan. 22, 2007, In Brief)...
Company is confident that data readout from pivotal trial could be ready before the end of 2020.